TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years Medtronic plc a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation Trial, which was presented as a Late Breaking Clinical Trial at the 33 rd Transcatheter Cardiovascular Therapeutics conference, the ...

TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late Breaking Clinical Trial at the 33 rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Data from the trial showed that the hemodynamic (blood flow) benefits of the Medtronic CoreValve™ and Evolut™ platforms were maintained at five years with an excellent safety profile and stable valve performance in patients with symptomatic, severe aortic stenosis who are at an intermediate risk for open-heart surgery.

At five years, rates of all-cause mortality were similar between TAVR with the CoreValve/Evolut platform and surgical aortic valve replacement (SAVR) (30.0% for TAVR versus 28.7% for SAVR; p=0.55), while rates of disabling stroke were also similar (4.1% for TAVR versus 5.8% for SAVR, p = 0.12). The TAVR arm continued to demonstrate durable valve longevity, as evidenced by better mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg; p

In the study, patients considered to be at intermediate risk for open-heart surgery had a risk of mortality of ≥ 3 and

"TAVR has revolutionized the treatment of aortic stenosis with more TAVR cases now performed than surgical aortic valve replacement for this disease. With this shift in treatment, longer-term, randomized data is increasingly important as we strive to better understand the lifetime management of these patients," said Michael Reardon , M.D., professor of cardiothoracic surgery and Allison Family Distinguished Chair of Cardiovascular Research at Houston Methodist DeBakey Heart & Vascular Center, principal investigator in the SURTAVI trial.

The global, prospective, multi-center, randomized SURTAVI Trial evaluated two early valve generations (CoreValve™, Evolut™ R) across a variety of valve sizes in 864 intermediate-risk symptomatic severe aortic stenosis patients. Patients in the TAVR arm were compared to 796 intermediate-risk patients who were randomized to open-heart surgery.

"These longer-term outcomes are remarkably similar after TAVR and surgery in patients with severe aortic stenosis at intermediate operative risk," said Nicolas Van Mieghem , M.D., Ph.D., professor of interventional cardiology, department of cardiology, Thoraxcenter, Erasmus University Medical Center in Rotterdam, The Netherlands , who presented the data at the meeting. "Additionally, results from this study are particularly impressive given the TAVR devices evaluated were first- and second-generation systems."

The Evolut TAVR platform, which includes the Evolut™ R, Evolut™ PRO, Evolut™ PRO+, and newest-generation Evolut™ FX valves, is indicated for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate and low) in the U.S.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, cranial and spinal robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:


Joey Lomicky

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-2494

+1-763-505-4626

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-self-expanding-tavr-platform-shows-excellent-longer-term-performance-at-five-years-in-surtavi-trial-301417401.html

SOURCE Medtronic plc

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/05/c9885.html

News Provided by Canada Newswire via QuoteMedia

Janssen to Showcase Progress on Respiratory Syncytial Virus Vaccine Candidate at ESWI 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) today announced it will present data from six company-sponsored studies in support of their respiratory syncytial virus (RSV) adult vaccine candidate at the Eighth European Scientific Working Group on Influenza (ESWI) meeting . The cornerstone of Janssen's presence at ESWI will be a series of presentations detailing findings from the Phase 2b CYPRESS trial in adults at increased risk for RSV.

Keep reading... Show less

Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month

Opioid-Induced Constipation Takes the Spotlight on TikTok

Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation Initiatives Aim to Spark Greater Awareness for These Conditions

Keep reading... Show less

Knight to Present at Stifel GMP's The Future of Healthcare Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the upcoming Stifel GMP Future of Healthcare Conference on Wednesday, December 8, 2021 at 10 am ET, that will be held virtually. A live webcast of the event will be available at the following link: Event . A copy of the presentation will be available at www.gud-knight.com .

About Knight Therapeutics Inc.

Keep reading... Show less

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

Keep reading... Show less

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Keep reading... Show less
Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

Keep reading... Show less

Top News

Related News